Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Background: Disparities in health status occur between people with differing socioeconomic status and disadvantaged groups usually have the highest risk exposure and the worst health outcome. We sought to examine the social disparities in the population prevalence of diabetes and in the development of treated end stage renal disease due to type 1 diabetes which has not previously been studied in Australia and New Zealand in isolation from type 2 diabetes.

Methods: This observational study examined the population prevalence of diabetes in a sample of the Australian population (7,434,492) using data from the National Diabetes Services Scheme and of treated end stage renal disease due to diabetes using data from the Australian and New Zealand Dialysis and Transplant Registry. The data were then correlated with the Australian Bureau of Statistics Socioeconomic Indexes for Areas for an examination of socioeconomic disparities.

Results: There is a social gradient in the prevalence of diabetes in Australia with disease incidence decreasing incrementally with increasing affluence (Spearman's rho = .765 p < 0.001). There is a higher risk of developing end stage renal disease due to type 1 diabetes for males with low socioeconomic status (RR 1.20; CI 1.002-1.459) in comparison to females with low socioeconomic status. In Australia and New Zealand Aboriginal and Torres Strait Islanders, Maori and Pacific Islanders appear to have a low risk of end stage renal disease due to type 1 diabetes but continue to carry a vastly disproportionate burden of end stage renal disease due to type 2 diabetes (RR 6.57 CI 6.04-7.14 & 6.48 CI 6.02-6.97 respectively p < 0.001) in comparison to other Australian and New Zealanders.

Conclusion: Whilst low socioeconomic status is associated with a higher prevalence of diabetes the inverse social gradient seen in this study has not previously been reported. The social disparity seen in relation to treated end stage renal disease due to type 2 diabetes for Aboriginal and Torres Strait Islanders, Maori and Pacific Islanders has changed very little in the past 20 years. Addressing the increasing incidence of diabetes in Australia requires consideration of the underlying social determinants of health.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5637272PMC
http://dx.doi.org/10.1186/s12889-017-4807-5DOI Listing

Publication Analysis

Top Keywords

prevalence diabetes
16
stage renal
12
renal disease
12
social disparities
8
diabetes
8
diabetes australia
8
disease diabetes
8
population prevalence
8
treated stage
8
prevalence
4

Similar Publications

Objective: To compare maternal and neonatal adverse outcomes between women who are English proficient (EP) and those who have limited English proficiency (LEP).

Design: Retrospective cohort study.

Setting: Single US academic medical centre with interpreter services.

View Article and Find Full Text PDF

Tree-based scan statistics (TBSS) are data mining methods that screen thousands of hierarchically related health outcomes to detect unsuspected adverse drug effects. TBSS traditionally analyze claims data with outcomes defined via diagnosis codes. TBSS have not been previously applied to rich clinical information in Electronic Health Records (EHR).

View Article and Find Full Text PDF

Background: Chronic kidney disease (CKD) management was largely centered around renin-angiotensin-aldosterone system inhibitors (RAASi) optimization, until recent emergence of novel therapeutics. However, slow adoption of guideline-directed therapy leaves patients vulnerable to disease progression. In 2022, a data-driven informatics approach was introduced to track real-time adherence to best practices.

View Article and Find Full Text PDF

Aims: The PARACHUTE-HF trial (NCT04023227) is evaluating the effect of sacubitril/valsartan compared with enalapril on a hierarchical composite of cardiovascular events (cardiovascular death, first heart failure hospitalization), and change in N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels in participants with heart failure and reduced ejection fraction (HFrEF) caused by chronic Chagas cardiomyopathy (CCC). We describe the baseline characteristics of participants in PARACHUTE-HF compared with prior HFrEF trials.

Methods And Results: PARACHUTE-HF, a multicentre, active-controlled, open-label trial, enrolled 922 participants with confirmed CCC, New York Heart Association (NYHA) functional class II-IV, and left ventricular ejection fraction (LVEF) ≤40%.

View Article and Find Full Text PDF

Adiponectin as a Predictor of Metabolic Dysfunction-Associated Steatotic Liver Disease and Non-Alcoholic Fatty Liver Disease: A 17-Year Korean Cohort Study.

Diabetes Metab J

September 2025

Department of Epidemiology and Health Promotion, Institute for Health Promotion, Graduate School of Public Health, Yonsei University, Seoul, Korea.

Background: This study aimed to investigate the association between adiponectin levels and the incidence of metabolic dysfunction- associated steatotic liver disease (MASLD) and nonalcoholic fatty liver disease (NAFLD), and to explore the predictive value of adiponectin in the onset of these conditions.

Methods: A 17-year follow-up of 35,026 individuals from the Korean Cancer Prevention Study-II biobank cohort (2004-2021) was conducted. Adiponectin levels were categorized into quintiles.

View Article and Find Full Text PDF